Recent news highlights include corporate actions related to Nasdaq compliance, regulatory approvals, product publications, and dividend announcements.

• Scilex Holding Company announced deferral of preferred stock dividend record date in June 2025 [N5].
• The company reported publication on GLOPERBA dosing adjustments in a peer-reviewed journal in June 2025 [N6].
• Scilex regained compliance with Nasdaq minimum closing bid price requirement as of April 30, 2025 [N7].
• Scilex won Health Canada approval for ELYXYB to treat acute migraine with or without aura in April 2025 [N6].
• The FDA granted orphan drug designation for colchicine to treat pericarditis and for Gloperba for the treatment of pericarditis in April 2025 [N8].
• Scilex announced a 1-for-35 reverse stock split in April 2025 to regain Nasdaq compliance [N7].
• The company announced new record dates for preferred stock dividends in April 2025 [N8].

Scilex has a diversified portfolio of FDA-approved products and promising clinical candidates targeting significant unmet needs in pain management. Its commercial infrastructure and managed care strategies support product uptake. The company's novel delivery technologies and patent protections may provide competitive advantages. The adoption of a cryptocurrency treasury strategy could offer alternative asset growth and revenue streams. Successful commercialization of pipeline products and expansion of market access could enhance its position in the non-opioid pain management market.

Scilex faces substantial net losses and limited liquidity, with a current ratio of 0.08 indicating short-term financial constraints. The company depends on regulatory approvals for its clinical candidates, which carry inherent risks. Competition in pain management is intense, and market adoption of new products can be uncertain. The cryptocurrency treasury strategy introduces additional risk and regulatory uncertainty. Failure to achieve commercial milestones or secure adequate financing could adversely affect operations and growth prospects.

Scilex's moat is based on its portfolio of FDA-approved non-opioid pain management products and advanced clinical-stage candidates addressing large markets with unmet needs. Its proprietary delivery technologies, exclusive licensing agreements, and patent protections, such as for SEMDEXA and SP-103, create barriers to entry. The company's established commercial infrastructure, including a dedicated sales force and managed care relationships, supports market penetration. Additionally, the fast track designations and novel formulations may provide competitive advantages. However, the company faces risks from regulatory approvals, competitive products, and financial constraints.

• Regulatory Approval Risk: The company’s clinical-stage product candidates require FDA approval, which is uncertain and may delay or prevent commercialization.
• Financial and Liquidity Risk: Significant net losses and low liquidity ratios indicate financial constraints that may impact operations and development activities.
• Market Competition: The pain management market is competitive with existing and emerging therapies that may limit market share and pricing power.
• Cryptocurrency Treasury Strategy Risk: Investing treasury assets in cryptocurrencies exposes the company to market volatility, regulatory changes, and custody risks.

• Scilex Holding Co is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain treatment [S1].
• The company targets indications with high unmet needs and large market opportunities using non-opioid therapies [S1].
• Commercial products include: ZTlido (lidocaine topical system) 1.8%, FDA-approved for neuropathic pain associated with postherpetic neuralgia; ELYXYB, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults; and GLOPERBA, the first FDA-approved liquid oral colchicine for gout prophylaxis, launched June 2024 [S1].
• Product candidates include SP-102 (SEMDEXA), a viscous gel corticosteroid for epidural injections to treat sciatica with completed Phase 3 study; SP-103, a triple-strength lidocaine topical system for acute pain with completed Phase 2 trial; and SP-104, a low-dose delayed-release naltrexone for fibromyalgia with completed Phase 1 trials [S1].
• The company has a commercial sales force of over 30 people targeting over 3,500 healthcare providers including primary care physicians, pain specialists, neurologists, and palliative care physicians [S1].
• ZTlido had approximately 5.6% market share of the lidocaine patch prescription market in covered US territories as of December 31, 2025 [S1].
• The company uses multi-channel marketing and managed healthcare account executives to secure formulary coverage for its products, including major payors and pharmacy benefit managers [S1].
• Scilex has adopted a cryptocurrency treasury strategy focusing on long-term holdings of Ethereum, bitcoin, BNB, Doge, and other blockchain-linked cryptocurrencies, with plans to grow holdings and generate revenue via staking and yield-generating activities [S1].
• Financial snapshot as of December 31, 2025: cash and equivalents $4.955 million, current assets $38.358 million, current liabilities $483.652 million, revenue $30.253 million, net loss $374.053 million, basic and diluted EPS -$36.48, current ratio 0.08, cash ratio 0.01 [S1].
• The company regained compliance with Nasdaq minimum closing bid price requirement as of April 30, 2025 [N7].
• Scilex received Health Canada approval for ELYXYB to treat acute migraine with or without aura as of April 15, 2025 [N6].
• The FDA granted orphan drug designation for colchicine to treat pericarditis and for Gloperba for the treatment of pericarditis in April 2025 [N8].
• The company announced a 1-for-35 reverse stock split in April 2025 to regain Nasdaq compliance [N7].
• Scilex announced deferral and changes of preferred stock dividend record dates in 2025 [N5, N8].
• The company reported publication on GLOPERBA dosing adjustments in a peer-reviewed journal in June 2025 [N6].